Patent · US Active

Methods and compositions for cancer treating conditions relating to over expressions of EphA2

US10501553B2 · kind B2 · utility

0Cited by

0References

27Claims

0Family size

Inventors

Dimitar B. Nikolov · New York, US
Juha Himanen · New York, US
Urpo Juhani Lamminmaki · Ilmarinen, FI
Hanna Sanmark · Turku, FI

Key dates

Filing date	Nov 18, 2015
Grant date	Dec 10, 2019
Priority date	—
Expiry date	Jan 18, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

An anti-EphA2 scFv single-chain antibody binds with high specificity for EphA2 and blocks ephrin binding to Eph-A2. The antibody may be linked with other antigen-targeting domains, such as an anti-CD20 domain, or conjugated with toxins, or used in combination therapy to for treatment of conditions related to overexpression of EphA2. The antibody may also be expressed in vivo by an expression vector that is designed to facilitate such treatment.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.